PubMed Health⌕ Search

Biomedical subjects

G Koschel

Publications and source records attributed to G Koschel.

25 records · Page 2Linked to original sources
PubMed1988

[Phase III therapy study in patients with small cell bronchial cancer].

In a prospective randomized study 150 patients with small cell lung carcinoma (80 cases with extended, 70 cases with limited disease) received either cisplatin + etoposide (DDP/VP) or cyclophosphamide + etoposide (cyclo/VP) as induction chemotherapy. Patients were crossed over when less than complete remission was achieved. Treatment failures received a salvage regimen with adriamycin + vindesine (ADM/VDS). Remission rates (complete + partial remissions) achieved with DDP/VP were 87.4% (40.6% + 46.8%) in limited disease and 72.2% (10.1% + 62.1%) in extended disease; response rates seen following cyclo/VP were 78.8% (31.5% + 47.3%) in limited and 51.0% (6.9% + 44.1%) in extended disease. Median survival time for patients in complete remission was 12.0 months following DDP/VP and 14 months following cyclo/VP; for patients in partial remission 10.0 and 9.0 months, respectively. The analysis of the treatment results shows an equal effectivity of both induction regimes which, however, seem to be largely cross resistant. DDP/VP probably causes more stable longtime remissions. The salvage regimen ADM/VDS was ineffective. The results achieved with this rather complex therapeutic strategy are not superior to those seen with simpler regimes.

Adult↗
PubMed1988

[Possibilities of chemotherapy in patients with bronchial cancer].

The introduction of chemotherapy in the treatment of small cell lung cancer made this a potentially curable disease. Despite intensive efforts, non-small cell lung cancer, however, remains refractory to chemotherapy. In patients with small cell lung cancer efforts are concentrating on increasing the cure rates. In patients with non-small lung cancer efforts are directed at achieving an optimal combination of palliative action and quality of life.

Adult↗
PubMed1987

[Chemotherapy of non-small cell bronchial cancer with mitomycin C, vindesine and cisplatin. Results of a phase II study].

Forty-five patients (39 male, 6 female) with inoperable non-small-cell lung cancer were treated with combined mitomycin C, vindesine and cisplatin. All patients had measurable disease and had no previously received chemotherapy. The performance status of all patients was over 60%. Twenty-one patients had limited, 24 extensive disease. The overall remission rate was 53.3% (3 complete and 21 partial remissions) with a median remission duration of 9 months. Adeno- and squamous cell carcinoma responded to the chemotherapy with a remission rate of 63% (7 out of 11 patients) and 58% (14 out of 24 patients), but there were only 30% responders in large cell carcinoma (3 out of 10 patients). The median survival time for responders was 12 months, for those with no change and for patients with progressive disease 6 months. Myelosuppression and renal toxicity of the combination was generally not a treatment problem; subjective tolerance, however, (gastrointestinal upset) was poor.

Adult↗
PubMed1985

[Computed tomographic findings in diffuse malignant pleural mesothelioma].

Malignant pleural mesothelioma is a rare tumour and often difficult to diagnose. In this report, the CT findings of 50 patients with proven malignant pleural mesothelioma are described and tabulated. In 31 cases the CT findings could be compared with the results of thoracotomy and thoracoscopy. CT proved reliable in evaluating the exact extent of the disease. Additionally, a combination of findings can be detected by CT, suggesting the diagnosis of malignant pleural mesothelioma. The limitations of CT in malignant pleural mesothelioma are discussed.

Adult↗
PubMed1985

[Malignant diffuse pleural mesothelioma: a comparison between computed tomography and the conventional chest x-ray].

The rate of incidence of malignant pleural mesothelioma is increasing although diagnosis of this disease may be very difficult. Computed tomography examinations and conventional chest x-rays of 30 patients with malignant pleural mesothelioma were reviewed independently, to evaluate the role of both modalities. CT offered the following advantages over conventional chest x-ray examinations: CT was more sensitive in detecting the smooth and nodular changes of malignant pleural mesothelioma, especially at the diaphragm and lower parts of the thorax, tumours could be better demonstrated at the pericardium and in the greater fissure, in some cases, where chest films showed just abnormal widening of the mediastinum, CT could differentiate between tumour involvement of the mediastinal pleura and local invasion of the mediastinum by the tumour, CT was more effective in detecting pleural calcifications and thickening of the contralateral pleura. CT proves more accurate in assessing the extent of the disease, and gives additional diagnostic help.

Adult↗
PubMed1983

[Combined chemotherapy-radiotherapy study of small cell bronchial carcinoma: chemo-/radiotherapy vs radio-/chemotherapy].

The authors studied the effect of a chemo-/radiotherapy or radio-/chemotherapy on 52 cases of microcellular bronchial carcinoma, classification "limited disease". The survival curves were slightly better for the patients submitted to primary chemotherapy, but the difference was not statistically significant, and the curves coincided again after 18 months. 60 to 80% of the patients had no complaints or only unimportant complaints during more than half of their survival time. In 23 patients with "extensive disease" who received only a symptomatic therapy or a combined palliative chemotherapy, chemotherapy had a slightly better effect, but this was not statistically significant.

Antineoplastic Agents↗